Skip to main content
Have a personal or library account? Click to login
Curving Tuberculosis: Current Trends and Future Needs Cover

Curving Tuberculosis: Current Trends and Future Needs

Annals of Global Health
Volume 85 (2019): Issue 1
By: B. Rojano,  J. A. Caminero and  M. Hayek  
Open Access
|Jan 2019
Figures & tables

Figures & Tables

Table 1

World Health Organization Classification of Tuberculosis Drugs.

GroupDrugs
A: FluoroquinolonesLevofloxacin, Moxifloxacin, Gatifloxacin
B: Second line injectable drugsStreptomycin, Amikacin, Kanamycin, Capreomycin
C: Other core second-line drugsEthionamide, Prothionamide, Cycloserine/Terizidone, Clofazimine, Linezolid
D: Non-core MDR-TB drugs

  1. High dose Isoniazid, Ethambutol, Pyrazinamide

  2. Bedaquiline, Delamanid

  3. Meropenem, Para-Aminosalicylic Acid, Imipenem-Cilastatin, Amoxicillin-Clavulanate, Clarithromycin

DOI: https://doi.org/10.5334/aogh.2415 | Journal eISSN: 2214-9996
Journal RSS Feed
Language: English
Published on: Jan 22, 2019
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2019 B. Rojano, J. A. Caminero, M. Hayek, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 85 (2019): Issue 1
Previous article
Next article